We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CCF
1801
DELISTED
Chase Corporation
CCF
| $2.39M | ﹤0.01% |
23,390
+3,096
| +15% | +$345K |
|
|
SPTN
1802
DELISTED
SpartanNash
SPTN
| $2.39M | ﹤0.01% |
109,047
-13,573
| -11% | -$273K |
|
|
RVNC
1803
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.38M | ﹤0.01% |
85,476
+3,013
| +4% | +$86K |
|
1804
Verra Mobility
VRRM
$744M
| $2.38M | ﹤0.01% |
157,727
+4,727
| +3% | +$72.2K |
|
1805
CEVA Inc
CEVA
$1.08B
| $2.37M | ﹤0.01% |
55,601
-8,280
| -13% | -$376K |
|
|
HSII
1806
DELISTED
Heidrick & Struggles
HSII
| $2.37M | ﹤0.01% |
53,158
-7,196
| -12% | -$303K |
|
|
DNB
1807
DELISTED
Dun & Bradstreet
DNB
| $2.37M | ﹤0.01% |
140,960
-10,748
| -7% | -$205K |
|
|
PRSU
1808
Pursuit Attractions and Hospitality Inc
PRSU
$1.25B
| $2.37M | ﹤0.01% |
52,172
-7,840
| -13% | -$351K |
|
|
TGH
1809
DELISTED
Textainer Group Holdings limited
TGH
| $2.37M | ﹤0.01% |
67,799
+2,052
| +3% | +$67.1K |
|
1810
Repay Holdings
RPAY
$327M
| $2.36M | ﹤0.01% |
102,447
+8,880
| +9% | +$208K |
|
1811
Travere Therapeutics
TVTX
$5.78B
| $2.36M | ﹤0.01% |
97,241
+3,009
| +3% | +$55.3K |
|
1812
AppFolio
APPF
$7.04B
| $2.36M | ﹤0.01% |
19,573
+652
| +3% | +$84.7K |
|
1813
Super Micro Computer
SMCI
$20.1B
| $2.36M | ﹤0.01% |
644,200
+16,350
| +3% | +$59.3K |
|
1814
Expro Ltd
XPRO
$1.91B
| $2.35M | ﹤0.01% |
133,515
+101,525
| +317% | +$1.72M |
|
1815
AdaptHealth
AHCO
$759M
| $2.35M | ﹤0.01% |
100,909
-3,486
| -3% | -$84.3K |
|
1816
Allogene Therapeutics
ALLO
$694M
| $2.33M | ﹤0.01% |
90,768
+2,938
| +3% | +$69.8K |
|
1817
American Well
AMWL
$230M
| $2.33M | ﹤0.01% |
12,793
-150
| -1% | -$32.5K |
|
1818
Vroom Inc
VRM
$48.2M
| $2.33M | ﹤0.01% |
1,319
-43
| -3% | -$109K |
|
1819
Playtika
PLTK
$1.12B
| $2.33M | ﹤0.01% |
84,250
+13,312
| +19% | +$331K |
|
|
NXGN
1820
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $2.33M | ﹤0.01% |
165,044
-18,607
| -10% | -$289K |
|
|
TRIL
1821
DELISTED
Trillium Therapeutics Inc.
TRIL
| $2.33M | ﹤0.01% |
132,421
+4,038
| +3% | +$47.2K |
|
1822
Harmonic Inc
HLIT
$1.28B
| $2.32M | ﹤0.01% |
265,331
-37,028
| -12% | -$331K |
|
1823
Riot Platforms
RIOT
$7.76B
| $2.32M | ﹤0.01% |
90,343
-2,621
| -3% | -$84.4K |
|
1824
Simulations Plus
SLP
$371M
| $2.31M | ﹤0.01% |
58,547
+10,218
| +21% | +$466K |
|
1825
Zentalis Pharmaceuticals
ZNTL
$302M
| $2.31M | ﹤0.01% |
34,666
+2,776
| +9% | +$160K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.